| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-09-16 | Scil Proteins (Germany) Martin Luther University Halle-Wittenberg (Germany) | gastrointestinal tumors. | R&D |
Cancer - Oncology | R&D agreement | |
| 2011-09-15 | Teva Pharmaceutical (Israel) Cocrystal Discovery (USA) | antiviral therapeutics | serious and chronic viral diseases | development |
Infectious diseases | Development agreement |
| 2011-09-15 | Arsanis (USA - MA) | nomination |
Infectious diseases | Nomination | ||
| 2011-09-13 | Novalix (France) Fondation Jerome Lejeune (France) | R&D |
Genetic diseases | R&D agreement | ||
| 2011-09-13 | Zobio (The Netherlands) Abbott (USA) | biophysics research services in the area of hit matter discovery and characterization | undisclosed | R&D |
R&D agreement | |
| 2011-09-13 | Oxford BioTherapeutics (UK) Seattle Genetics (USA - WA) | antibody-drug conjugates (ADC) for cancer | cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2011-09-12 | Ark Therapeutics Group (UK) PsiOxus Therapeutics (UK) | ColoAd1 programme | colorectal cancer | Manufacturing Production |
Cancer Oncology | |
| 2011-09-12 | Silence Therapeutics (UK) InteRNA Technologies (The Netherlands) | novel microRNA therapeutics | cancer | development |
Cancer - Oncology | Development agreement |
| 2011-09-08 | Sucampo Pharmaceuticals (USA) Numab AG (Switzerland) | antibody technology | R&D |
R&D agreement | ||
| 2011-09-07 | CMC Biologics (Denmark-USA) Oxford BioTherapeutics (UK) | CHEF1® expression system | licensing |
Licensing agreement | ||
| 2011-09-07 | Medigene (Germany) Pharmanova (Serbia) | Veregen® ointment (made from the extract of green tea leaves - catechins) | genital warts | licensing commercialisation |
Infectious diseases - Gynecology - Women's health | Licensing agreement |
| 2011-09-07 | Debiopharm (Switzerland) Ascenta Therapeutics (USA) | AT-406 (Inhibitor of Apoptosis Protein - called Debio 1143 by Debiopharm) | various undisclosed cancers | licensing |
Cancer - Oncology | Licensing agreement |
| 2011-09-07 | BiolineRx (Israel) Ramot (Israel) | BL-7050 | neuropathic pain - inflammatory pain | licensing |
Inflammatory diseases - CNS diseases | Licensing agreement |
| 2011-09-06 | Chiesi Farmaceutici (Italy) NiKem Research (Italy) | design, synthesis, hit validation, lead optimization, biochemical pharmacology and ADMET & PK profiling | asthma, COPD | R&D |
Respiratory diseases - Inflammatory diseases - Allergic diseases | R&D agreement |
| 2011-09-06 | Qiagen (The Netherlands) Eli Lilly (USA) | molecular companion diagnostic for a JAK2 inhibitor | myeloproliferative neoplasms | development |
Cancer - Oncology | Development agreement |
| 2011-09-05 | Evotec (Germany) Roche (Switzerland) | EVT 302 | Alzheimer’s disease | development |
Neurodegenerative diseases | Development agreement |
| 2011-09-02 | Oxford BioTherapeutics (UK) Lonza (Switzerland) | GS Gene Expression System™ | licensing |
Licensing agreement | ||
| 2011-09-02 | Addex Pharmaceuticals (Switzerland) Merck&Co (USA) | metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) program | Parkinson's disease | licensing |
Neurodegenerative diseases - CNS diseases | Licensing agreement |
| 2011-09-02 | AM-Pharma (The Netherlands) | nomination |
Inflammatory diseases | Nomination | ||
| 2011-09-01 | Pevion Biotech (Switzerland) CSL (Australia) | PEV7 therapeutic vaccine | Recurrent Vulvovaginal Candidiasis | licensing |
Infectious diseases - Gynecology - Women's health | Licensing agreement |
